Dana-Farber Cancer Institute | Boston, MA
Dana-Farber Cancer Institute (DFCI) is seeking a Director of Operations Quality for its Hematopoietic Stem Cell Transplant (HSCT) & Immune Effector Cell Therapy Programs (IEC). This is a mission critical and highly visible operational leadership role reporting into the nationally recognized Division of Stem Cell Transplantation and Cellular Therapies at the Institute. The combined programs are among the largest in the country and serve adult and pediatric patients and families of DFCI, Brigham & Women’s Hospital, and Boston Children’s Hospital. All three institutions are Harvard Medical School (HMS) teaching affiliates.
The Director of Operations Quality for the Hematopoietic Stem Cell Transplant (HSCT) & Cellular Therapies Programs provides leadership and direction to ensure operational excellence across a broad range of activities and sites for two of the largest and most respected HSCT and Cellular Therapies programs in the U.S. Working collaboratively with faculty and staff to develop and implement strategies to achieve programmatic excellence, this position will rely on a deep understanding of clinical operations in a large and highly complex care delivery system to successfully build and socialize methods to optimize effective operations. The Director will serve as a key leader for programmatic interests in overall operational effectiveness and innovative solutions that ensure patient safety, regulatory compliance, clinical templates, and electronic and other tools to support improvements in utilization and outcomes. The Director will also ensure the accuracy and reliability of documentation that supports clinical pathways, outcomes reporting and analytics, revenue integrity, business planning, and well-engineered day to day workflows. The Director will ensure positive and supportive interface with regulatory organizations and effective working relationships with commercial organizations to implement new products. The Director will also create and maintain programs to ensure staff readiness and training, and process improvements that support financial performance. The Director will serve as a key consultant and provide guidance to other programmatic leads across sites of care, including inpatient and outpatient clinical operations, institutional facilities teams, clinical and cell processing laboratories, patient coordination, donor services, community-based care, referring physician relations, business analytics, financial planning and strategic planning. The Director reports to the Vice President for the HSCT & Cellular Therapies Service Line. The Director’s team of 20 staff members includes quality assurance and improvement managers and specialists, outcomes reporting and program administrators, and an audit team.
The Director of Operations Quality (the Director) reports to the Vice President, HSCT & Cellular Therapy Service Line Operations. S/he leads a team of 20 staff members, including quality assurance and improvement managers and specialists, outcomes reporting and program administrators, and an audit team for both adult and pediatric programs. The Director will oversee a dedicated operating budget for quality operations with support from the Division’s financial analyst for day to day financial transactions. The Director is a key member of the clinical leadership team working closely with the Medical Directors and executives providing consultation and guidance relative to quality assurance and operational effectiveness. The Director will provide advisory and informational support to administrative leadership and other institutional executives and officials across the sites of care relative to transplant and cellular therapy operations quality and will play a leading role in informing and educating all staff involved with cellular therapies across the organizations as needed regarding standards and operational methods necessary to comply with such standards. The Director is responsible for overseeing and managing the transplant and cell therapies quality management program, serving as the quality officer for these services and licenses, ensuring regulatory compliance methodology and documentation, continuous quality and process improvement, outcomes reporting, patient safety safeguards, and global education across the organizations. The Director ensures full integration of the program’s quality systems with the organizations’ patient safety and risk management enterprises and serves as the key quality contact for the program for other leaders in the institution. The Director will oversee the program’s clinical outcomes data enterprise, including reporting to the national repository, meeting regulatory requirements for data quality, and working with the organization’s analytics program to ensure reliable data consolidation for broad utilization for research, quality improvement and business purposes. She/he is expected to lead and support quality research and improvement initiatives internally and as a representative of the organization for national or multi-site quality projects. It is important to note that Dana-Farber is presently implementing an all new data repository application to support case management, outcomes and reporting to the CIBMTR, with go-live scheduled for March 2019. The quality staff are heavily involved in this critically important implementation that is simultaneously revising many workflows and communication pathways. Working closely with clinical staff, duties include: oversight of the development, updating and dissemination of standard operating procedures for clinical practices that fall under regulatory control; monitoring and reporting on stem cell transplantation and other cell therapy clinical key indicators; performing and managing responses to clinical process audits; and managing planned and unplanned deviation reporting and trend analysis. Directing the efforts of three quality managers and a quality assurance team, the Director will oversee the coordination of FACT, FDA, JC, AABB, and other relevant compliance reporting and re-accreditation and inspection readiness requiring a full understanding of all relevant quality standards, ensuring that all regulatory and internal outcomes driven operating procedures are implemented and tracked. The Director will support clinical leadership in the development of treatment plans, consents, and forms as needed to ensure structured clinical practices. The Director will appropriately direct and support the quality managers or personally participate contemporaneously in deviation and adverse event documentation and assessment and play a lead role in subsequent root cause analysis and corrective action. The Director will play a lead role in the development of uniform training standards, procedures and documentation of competencies for all staff engaged in the coordination and care of transplant and cell therapy patients and donors. The Director organizes, plans and moderates various committee meetings and presents and ensures quality outcomes implementation as needed.
For More Information
Referrals and nominations are welcomed. Interested parties please send a letter of interest and resume to DFCI.DirOpsQualityTransplant2257@ZurickDavis.com. For questions and additional information, please contact Janet Clifford (email@example.com) or Jacqueline Rosenthal at 781.938.1975. All communication with ZurickDavis will remain confidential.
We welcome nominations and referrals of prospective candidates. Interested parties, please send resume and cover letter to DFCI.DirOpsQualityTransplant2257@ZurickDavis.com.